Heparin Or Derivative Patents (Class 514/56)
  • Patent number: 11903963
    Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 20, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Jian Liu, Zhangjie Wang, Po-Hung Hsieh, Yongmei Xu
  • Patent number: 11865137
    Abstract: Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: January 9, 2024
    Assignees: The University of North Carolina at Chapel Hill, The Research Foundation for the State University of New York
    Inventors: Katelyn Arnold, Ding Xu, Yongmei Xu, Rafal Pawlinski, Jian Liu
  • Patent number: 11833169
    Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: December 5, 2023
    Assignees: MUDANJIANG YOUBO PHARMACEUTICAL CO., LTD., JIUZHITANG CO., LTD.
    Inventors: Jinhua Zhao, Zhenguo Li, Na Gao, Mingyi Wu, Yanming Chen, Longyan Zhao, Yongsheng Wu, Zi Li, Chuang Xiao, Shunliang Zheng, Zhiyuan Nan, Jianbo Zhou, Jianping Xu, Lutan Zhou, Yafang Guo, Hongbo Qin, Jikai Liu
  • Patent number: 11834560
    Abstract: The present invention relates to a water degradable film comprising hyaluronic acid or a salt thereof and polyphenol compounds. The film of the present invention can transcribe nanofilms in the form of CNT (carbon nanotube), graphene and magnetic particles to various places. The film of the present invention can be dissolved by an aqueous solution or body fluid, and can be effectively used in the medical field since it is non-toxic and biocompatible. The film of the present invention can also be effectively used as a transcript that does not degrade the quality and performance of the device because no residue remains in the electronic device and the existing photolithography process.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: December 5, 2023
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Jae-Hyeok Lee, Sun-Hyun Park, Ki-Suk Kim
  • Patent number: 11806362
    Abstract: Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: November 7, 2023
    Assignee: Agency for Science, Technology and Research
    Inventors: Raymond Alexander Alfred Smith, Simon McKenzie Cool, Victor Nurcombe, Sadasivam Murali
  • Patent number: 11779646
    Abstract: The present disclosure features a protein-polymer conjugate, including a multivalent polymer building block, a stimuli-responsive protein covalently conjugated to the multivalent polymer building block to provide a protein-polymer conjugate, wherein the protein undergoes a modification upon exposure to a predetermined stimulus, and the protein modification triggers a physical and/or chemical response in the protein-polymer conjugate.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 10, 2023
    Assignee: University of Washington
    Inventors: Cole Alexander DeForest, Jared Shadish, Luman Liu
  • Patent number: 11771311
    Abstract: Disclosed here are systems and methods for collecting and/or screening of a pancreatic secretion, using a capsule endoscope comprising an imaging system and a trypsin sensor, and a tether coupled to the capsule endoscope.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: October 3, 2023
    Assignee: AnX Robotica Corp
    Inventors: Xiaodong Duan, Guohua Xiao, Kevin Rubey
  • Patent number: 11767613
    Abstract: A method of making a medical implant is provided by electrospinning a polymer solution to form a preform around a mandrel. The formed preform distinguishes an inner surface and an outer surface. The formed preform is removed from the mandrel and flipped inside-out resulting in the inner surface of the formed preform becoming the outer surface of the inside-out flipped preform, and the outer surface of the formed preform becoming the inner surface of the inside-out flipped preform. At least part of the inside-out flipped preform forms the medical implant such as e.g. an artificial heart valve, an artificial leaflet, an artificial graft, or an artificial vessel. The products made according to the method of this invention greatly improve the performance and durability of the medical implant.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 26, 2023
    Assignee: Xeltis AG
    Inventors: Jurgen Sander Miedema, Martijn Antonius Johannes Cox, Christophe Pierre Edouard Naz
  • Patent number: 11701380
    Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: July 18, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Jian Liu, Zhangjie Wang, Po-Hung Hsieh, Yongmei Xu
  • Patent number: 11633424
    Abstract: Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: April 25, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Jian Liu, Jine Li, Guowei Su, Rafal Pawlinski, Erica Sparkenbaugh
  • Patent number: 11628239
    Abstract: Skeletonized blood vessels for use as vascular grafts are protected from biomechanical injury and/or certain cellular and extracellular changes by application of a biocompatible hydrogel to the vessel exterior. The hydrogel may be applied to the vessel graft before or after harvesting from a donor patient.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: April 18, 2023
    Assignees: University of Delaware, The Nemours Foundation
    Inventors: Robert Akins, Kristi L. Kiick, Karyn Robinson, Rebecca Scott
  • Patent number: 11622752
    Abstract: Disclosed here are kits comprising pre-packed stabilizing solutions for stabilizing combinations of biomarkers demonstrating sufficient accuracy and specificity for identifying kidney injuries. Such kits can be better adapted for sample collection at a subject's dwelling, thus easing the burdensome requirement of continuous monitoring for kidney injury.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: April 11, 2023
    Assignee: NEPHROSANT, INC.
    Inventors: Robert Zawada, Corinne Mark, Christopher Goulart
  • Patent number: 11591638
    Abstract: A method for stabilizing cell-free nucleic acids. The method includes providing a composition and applying the composition to a biological sample as a stabilizing agent for the cell-free nucleic acids contained in the biological sample. The composition includes at least one buffering compound that buffers to a pH value of 7 or below, at least one anticoagulant and urotropin in aqueous solution.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: February 28, 2023
    Assignee: Sarstedt AG & Co. KG
    Inventors: Martin Kämper, Tim Kinitz
  • Patent number: 11564970
    Abstract: Compositions and methods for combinatorial drug discovery in nanoliter droplets are described. Novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infection are disclosed.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: January 31, 2023
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Paul Blainey, Anthony Kulesa, Jared Kehe
  • Patent number: 11535894
    Abstract: Specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with deep vein thrombosis (DVT) and related pathologies, such as pulmonary embolism (PE).
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: December 27, 2022
    Assignee: GENE GENDER S.R.L.
    Inventors: Goranka Tanackovic Abbas-Terki, Joëlle Michaud Schutz, Thierry Daniel Pache
  • Patent number: 11492421
    Abstract: The present invention provides an improved process for the preparation of Dalteparin sodium. The process is simple, commercially viable and industrially advantageous.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: November 8, 2022
    Inventors: Vamsee Krishna Chintakunta, Manohar Sarma Vedula, Narender Dev Mantena, Rajasekhar Kadaboina
  • Patent number: 11446361
    Abstract: The invention relates to an anti-thrombotic molecule having both antiplatelet and anticoagulant (APAC) activity; its use as a medicament; its selective configuration and use as an anticoagulant and platelet inhibitor, or its selective configuration and use, predominantly, as either an anticoagulant or a platelet inhibitor; and a method for its production.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: September 20, 2022
    Assignee: Aplagon Oy
    Inventor: Riitta Lassila
  • Patent number: 11299558
    Abstract: The present invention provides an improved process for the preparation of Enoxaparin sodium. The process is simple, commercially viable and industrially advantageous.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 12, 2022
    Inventors: Manohar Sarma Vedula, Sreedhar Kosgi, Narender Dev Mantena, Ratnakar Aryasomayajula
  • Patent number: 11090327
    Abstract: Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: August 17, 2021
    Assignee: Glycologix, LLC
    Inventor: Thomas H. Jozefiak
  • Patent number: 11083754
    Abstract: Embodiments of various aspects described herein relate to methods, kits, and cell culture media for generation of podocytes from pluripotent stem (PS) cells, as well as cells produced by the same, and methods of use.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 10, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Samira Musah
  • Patent number: 11033499
    Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 15, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Simon Bjerregaard Jensen, Per Sauerberg, Flemming S. Nielsen, Betty L. Pedersen, Erik Skibsted
  • Patent number: 11026942
    Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: June 8, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Haruhisa Inoue, Takayuki Kondo
  • Patent number: 11007149
    Abstract: Provided herein is a pharmaceutical composition for treating cancers. The pharmaceutical composition includes an oil-in-water (o/w) microemulsion, and an active pharmaceutical ingredient dissolved therein. The o/w microemulsion is comprised of an aqueous solution, an oil, and a surfactant, and is about 5-250 nm in diameter. Also provided herein are methods for treating cancers by use of the present pharmaceutical composition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: May 18, 2021
    Assignee: I-SHOU UNIVERSITY
    Inventors: Mei-Hwa Lee, Hung-Yin Lin
  • Patent number: 10875936
    Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glycosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glycosaminoglycan derivatives are obtained from natural or synthetic glycosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glycosaminoglycan by oxidation of said glycosaminoglycan.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: December 29, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 10688249
    Abstract: The present invention discloses novel devices, methods, and formulations for multiple dose delivery of an appropriate formulation of Heparin or low molecular weight heparin or a heparin-like compound. Multiple dose formulations of fondaparinux sodium, and preparation methods thereof, are also disclosed.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: June 23, 2020
    Assignees: Virchow Biotech Pvt. Ltd., Virchow Biotech Inc.
    Inventors: Hemanth Nandigala, Murali Krishna Reddy Tummuru, Prasad Vure, Radha Madhavi Dandu, Chiranjeevi Kondiparthi
  • Patent number: 10624866
    Abstract: The present disclosure relates to a pharmaceutical composition or food composition including Evans blue for prevention or treatment of chronic pain diseases. The administration of Evans blue according to the present disclosure can effectively reduce chronic pain, such as neuropathic pain. In particular, Evans blue targets mainly VNUT protein of dorsal root ganglia, which plays an important role in the secretion of ATP from the distal end of the afferent nerve and can relieve the pain using drugs continuously without side effects so that it can be efficiently used as an analgesic for various kinds of pain caused by chronic pain diseases.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: April 21, 2020
    Assignee: THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Won Hyung Lee, Dong Woon Kim, Jin Pya Hong, Yu Hua Yin
  • Patent number: 10500225
    Abstract: The present invention concerns a novel, sterile and injectable aqueous composition, that is heat-sterilised, comprising at least crosslinked hyaluronic acid, or one of the salts of same, and one or more fatty acids, characterised in that the mass proportion of water is greater than 51% of the total mass, the mass proportion of fatty acid is less than 45% of the total mass, the viscoelasticity properties are such that the ratio G?/G? at 0.7 Hz is less than 0.70; a method for preparing said composition; and the use of said composition for aesthetic and therapeutic applications.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: December 10, 2019
    Assignee: KH MEDTECH SÁRL
    Inventor: Benedicte Vincente Tauzin
  • Patent number: 10493012
    Abstract: Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 3, 2019
    Assignees: Agency for Science, Technology and Research, L'Oreal
    Inventors: Simon Cool, Victor Nurcombe, Charbel Bouez, Diah Saraswati Bramono
  • Patent number: 10206392
    Abstract: The present invention relates to a disinfecting composition which requires a shorter contact time to be effective than similar compositions. Also, provided is a method of disinfecting a surface with the disinfecting composition where a shorter contact time is needed to disinfect the surface.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 19, 2019
    Assignee: Lonza, Inc.
    Inventors: Andrew Kloeppel, James Bargmann
  • Patent number: 10188110
    Abstract: A catheter lock solution includes a hydrochloric acid solution having a concentration of 0.3 Molar to 1.0 Molar. This hydrochloric acid solution may be used to lock a catheter and/or salvage an infected catheter.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: January 29, 2019
    Assignee: Teleflex Medical Incorporated
    Inventors: Nisha Gupta, Elaine Steinke, Joel Rosenblatt
  • Patent number: 10172938
    Abstract: A responsive hydrogel-based material may be used as a carrier system for the in situ delivery of various cargo substances, including bioactive moieties. The hydrogel structure, which includes photodegradable and thioether moieties in its three dimensional network, enables finely tuned local release of cargo substances as a function of the in vivo tissue environment (e.g., enzyme concentration or reducing environment) and externally applied stimuli (e.g., light) by selective spatiotemporal hydrogel degradation.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 8, 2019
    Assignees: University of Delaware, The Regents of the University of California
    Inventors: Kristi L. Kiick, April M. Kloxin, Prathamesh M. Kharkar, Raja Sivamani, Emanual Maverakis
  • Patent number: 10023659
    Abstract: The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Dilafor AB
    Inventors: Per-Olov Eriksson, Erik Yngve Holmer
  • Patent number: 10021876
    Abstract: A composition that can solvate biofilms and disrupt bacterial cell walls acts to both kill the bacteria by cell lysis and remove the biofilm. This solvent-containing composition is effective against a broad spectrum of microbes and can be used on a variety of surfaces, both living and inanimate. The polarity of the solvent component of the composition is lower than that of pure water so that the composition exhibits increased efficacy in solvating the macromolecular matrix of a biofilm and in penetrating bacterial cell walls.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 17, 2018
    Assignee: Next Science IP Holdings Pty Ltd
    Inventor: Matthew Franco Myntti
  • Patent number: 9999649
    Abstract: Provided are a cosmetic composition and pharmaceutical composition for wound healing capable of efficiently performing collagen synthesis in skin, wherein the compositions contain, as an active ingredient, YIGSR peptide having the amino acid sequence of SEQ ID NO: 1 or a peptide derivative having a palmitoyl group added to an N-terminal of the peptide.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 19, 2018
    Assignee: NOVACELL TECHNOLOGY INC.
    Inventors: Tae Hoon Lee, Jae Yoon Kim, Jong Hyuk Yoon, Beom Joon Kim
  • Patent number: 9861655
    Abstract: The present invention relates to advanced topical formulations of pharmaceutically acceptable salts of Heparin providing enhanced transdermal penetration. The present invention provides clear, non-sticky liquid formulations in which the drug is ready-for-absorption and which are suitable for administration in the form of a solution or a spray. The topical formulations of the present invention do not form flaky or gel-like film on skin surface upon topical application.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: January 9, 2018
    Assignee: Troikaa Pharmaceuticals Limited
    Inventors: Ketan R. Patel, Milan R. Patel, Asheel K. Patel, Prakash J. Shah
  • Patent number: 9833618
    Abstract: Methods for treating a disease condition in a subject are provided. The subject methods include selectively modulating at least one biological activity of advential tissue in a manner effective to treat the disease condition. Also provided are compositions, kits and systems for use in practicing the subject methods.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: December 5, 2017
    Assignee: Palo Alto Investors
    Inventor: Anthony Joonkyoo Yun
  • Patent number: 9649499
    Abstract: A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: May 16, 2017
    Assignee: Medtronic ATS Medical, Inc.
    Inventor: Brian Pederson
  • Patent number: 9629914
    Abstract: Biomaterial compositions that include an isolated heparosan polymer are disclosed, as well as kits containing such biomaterial compositions and methods of producing and using such biomaterial compositions.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: April 25, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Paul L. DeAngelis
  • Patent number: 9629856
    Abstract: The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: April 25, 2017
    Assignee: Anteis SA
    Inventor: Frank Dreher
  • Patent number: 9480702
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • Patent number: 9480701
    Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Stefania Tiddia, Lino Liverani
  • Patent number: 9475888
    Abstract: The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: October 25, 2016
    Assignee: Dilafor AB
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson
  • Patent number: 9259389
    Abstract: The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1% by weight of the total weight of the formulation, b), a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70% by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30% by weight of the total weight of the formulation, d) at least one hydrophilic surfact
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: February 16, 2016
    Assignees: ENDOTIS PHARMA, CATALENT FRANCE BEINHEIM SA
    Inventors: Julien Meissonnier, Nathalie Sicre, Guillaume Sabate, Guy Dubreucq, Vanessa Nancy-Portebois, Maurice Petitou
  • Patent number: 9212233
    Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: December 15, 2015
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
  • Patent number: 9205106
    Abstract: The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia.
    Type: Grant
    Filed: September 7, 2009
    Date of Patent: December 8, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon McKenzie Cool, Victor Nurcombe
  • Patent number: 9155756
    Abstract: This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. The invention provides a novel use of a known medicament, i.e., pentasaccharide-depleted heparin, for use in the treatment or prevention of sepsis, systemic inflammatory response syndrome, severe sepsis or septic shock.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 13, 2015
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Gerardus Anna Franciscus Nicolaes, Christiaan Peter Maria Reutelingsperger, Hendrik Coenraad Hemker
  • Patent number: 9062194
    Abstract: A method for preparing a solid composite material comprising a structural polymer matrix and a thermo-responsive hydrogel involves forming a substantially homogeneous blend of a cross-linkable compound and monomer, oligomer or polymer particles in a blended aqueous liquid, inducing the cross-linkable compound to cross-link to form the thermo-responsive hydrogel and forming the structural polymer matrix from the structural polymer by a further induction means, wherein the resulting solid composite material provides a textile or membrane which presents a thermally insulating layer, through which air and/or liquid water cannot easily pass at low temperatures, but which also provides a more open structure at higher temperatures so that air and moisture vapor can pass through the textile or membrane.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: June 23, 2015
    Assignees: WETENSCHAPPELIJK EN TECHNISCH CENTRUM VAN DE BELGISCHE TEXTIELNIJVERHEID, UNIVERSITEIT GENT
    Inventors: Geert Hebbrecht, Peter Dubruel, Myriam Vanneste, Jan Laperre, Etienne Schacht, Jorg Schelfhout
  • Publication number: 20150147379
    Abstract: The embodiments relate generally to medical devices and to methods of their manufacture. One aspect provides devices including chitosan fibers that are a free of chemical cross linking. Another aspect provides a method of manufacturing such devices.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 28, 2015
    Applicant: COOK MEDICAL TECHNOLOGIES LLC
    Inventor: Mohammad Z. Albanna
  • Publication number: 20150140106
    Abstract: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 21, 2015
    Inventor: Shaker A. Mousa
  • Publication number: 20150139938
    Abstract: The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 21, 2015
    Applicant: Ohio State Innovation Foundation
    Inventors: Chandan Sen, Cameron Rink, Sashwati Roy, Greg Christoforidis